Literature DB >> 18627291

Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids.

Katerina Oikonomopoulou1, Kristina K Hansen, Amos Baruch, Morley D Hollenberg, Eleftherios P Diamandis.   

Abstract

Immunoassay measurements of human kallikrein-related peptidases (KLKs) such as prostate-specific antigen (KLK3) are of great value as diagnostic indices of cancer. Despite extensive knowledge of the abundance of immunoreactive KLKs in normal and cancer-related settings, there is little information available about the proportion of immunoreactive KLK that represents active enzyme in such samples. Using KLK6 as a prototype enzyme, we have developed an assay using a serine proteinase-targeted activity-based probe coupled to antibody capture. By employing activity-based labeling, we were able to quantify the proportion of enzymatically active relative to total immunoreactive KLK6 in crude cerebrospinal fluid from routine analyses and ascites fluid from ovarian cancer patients, as well as in supernatants from cancer cell lines. Our approach allowed monitoring of pro-KLK6 conversion to its active enzyme species and demonstrated that up to 5% of immunoreactive KLK6 detected in clinical samples represents active enzyme. We suggest that this new activity-based probe assay will prove of value as a complement to routine KLK immunoassay measurements for validating KLKs as cancer biomarkers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627291     DOI: 10.1515/BC.2008.086

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

1.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

2.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 3.  Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Authors:  Michael Blaber; Hyesook Yoon; Maria A Juliano; Isobel A Scarisbrick; Sachiko I Blaber
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

Review 4.  Activity-Based Probes for Proteases Pave the Way to Theranostic Applications.

Authors:  Georgia Sotiropoulou; Eleni Zingkou; Evangelos Bisyris; Georgios Pampalakis
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

5.  Novel specific activity-based probes validate KLK proteases as druggable targets.

Authors:  Georgia Sotiropoulou; Eleni Zingkou; Georgios Pampalakis
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

Review 6.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

Review 7.  Neutrophil Elastase Activity Imaging: Recent Approaches in the Design and Applications of Activity-Based Probes and Substrate-Based Probes.

Authors:  Natacha Jugniot; Pierre Voisin; Abderrazzak Bentaher; Philippe Mellet
Journal:  Contrast Media Mol Imaging       Date:  2019-06-12       Impact factor: 3.161

8.  Kallikrein-Related Peptidase 6 (KLK6) as a Contributor toward an Aggressive Cancer Cell Phenotype: A Potential Role in Colon Cancer Peritoneal Metastasis.

Authors:  Hayet Bouzid; Feryel Soualmia; Katerina Oikonomopoulou; Antoninus Soosaipillai; Francine Walker; Khaoula Louati; Rea Lo Dico; Marc Pocard; Chahrazade El Amri; Natalia A Ignatenko; Dalila Darmoul
Journal:  Biomolecules       Date:  2022-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.